Comparison of ﬁxed-dose combinations for asthma 1879 Acknowledgements The authors would like to thank Esther Race (PhD) from MediTech Media Ltd, London, UK, who pro- vided medical writing support on behalf of Astra Zeneca. The manuscript is not under consideration elsewhere and none of the manuscript’s contents have been previously published. All authors have read and approved the manuscript. This work was supported by AstraZeneca. References 1 British Thoracic Society, Scottish Intercollegiate Guidelines Net- work. British Guideline on the Management of Asthma, a National Clinical Guideline. http://www.brit-thoracic.org.uk/ (accessed June 2008). 2 Global Initiative for Asthma. Global Strategy for Asthma Manage- ment and Prevention. http://www.ginasthma.com (accessed April 2008). 3 Desfougeres J-L, Sohier B, Freedman D et al. Has asthma control improved since AIRE? Results of a survey in 5 European countries. Eur Respir J 2007; 30: 249s. 4 Bateman ED, Boushey HA, Bousquet J et al. Can guideline-deﬁned asthma control be achieved? The Gaining Optimal Asthma Con- troL study. Am J Respir Crit Care Med 2004; 170: 836–44. 5 Gibson PG, Powell H, Ducharme FM. Differential effects of main- tenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007; 119: 344–50. 6 O’Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–7. 7 Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled for- moterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–11. 8 Marceau C, Lemiere C, Berbiche D et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006; 118: 574–81. 9 Stempel DA, Stoloff SW, Carranza Rosenzweig JR et al. Adherence to asthma controller medication regimens. Respir Med 2005; 99: 1263–7. 10 Stoloff SW, Stempel DA, Meyer J et al. Improved reﬁll persistence with ﬂuticasone propionate and salmeterol in a single inhaler com- pared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245–51. 11 Bateman ED, Bantje TA, Joao GM et al. Combination therapy with single inhaler budesonide ⁄ formoterol compared with high dose of ﬂuticasone propionate alone in patients with moder- ate persistent asthma. Am J Respir Med 2003; 2: 275–81. 12 Lalloo UG, Malolepszy J, Kozma D et al. Budesonide and formo- terol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moder- ate asthma. Chest 2003; 123: 1480–7. 13 Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 microg and ﬂuticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34. 14 Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide ⁄ formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262–8. 15 Angus R, Reagon R, Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol ⁄ ﬂuticasone propionate combination. Int J Clin Pract 2005; 59: 156–62. 16 Aalbers R, Backer V, Kava TT et al. Adjustable maintenance dosing with budesonide ⁄ formoterol compared with ﬁxed-dose salmeter- ol ⁄ ﬂuticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225–40. 17 Dahl R, Chuchalin A, Gor D et al. EXCEL: a randomised trial comparing salmeterol ⁄ ﬂuticasone propionate and formoterol ⁄ budesonide combinations in adults with persistent asthma. Respir Med 2006; 100: 1152–62. 18 Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide ⁄ formo- terol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725–36. 19 Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide ⁄ formoterol in a single inhaler. Curr Med Res Opin 2007; 23: 1809–20. 20 Lasserson TJ, Cates CJ, Ferrara G Combination ﬂuticasone and salmeterol versus combination budesonide and formoterol for chronic asthma in adults and children (Protocol). Cochrane Data- base Syst Rev 2007; Issue 3. Art. No.: CD004106. doi:10.1002/ 14651858.CD004106.pub2. 21 Jaeschke R, Mejza F, Lesniak W et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med 2007; 175: A57. 22 Nelson HS, Beasley R, Yancey SW et al. No increase in asthma- related hospitalizations following the addition of salmeterol to an inhaled corticosteroid in patients with asthma: a meta-analysis. Am J Respir Crit Care Med 2007; 175: A59. 23 Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide ⁄ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819–28. 24 Bousquet J, Boulet LP, Peters MJ et al. Budesonide ⁄ formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol ⁄ ﬂuticasone. Respir Med 2007; 101: 2437–46. 25 Jonsson B, Berggren F, Svensson K et al. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respir Med 2004; 98: 1146–54. 26 Rosenhall L, Borg S, Andersson F et al. Budesonide ⁄ formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract 2003; 57: 662–7. 27 Bender BG, Pedan A, Varasteh LT. Adherence and persistence with ﬂuticasone propionate ⁄ salmeterol combination therapy. J Allergy Clin Immunol 2006; 118: 899–904. Paper received April 2008, accepted July 2008 ª 2008 Ingenix Pharmaceutical Services (UK) Ltd. Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, December 2008, 62, 12, 1870–1879